Protein aggregation, denaturation, and loss of potency often occur during Protein A chromatography due to the harsh acidic conditions required for antibody elution. This study presents a pH ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...

Davis, chairman and chief executive officer, Merck. "We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave ...

A biotech company is suing Merck & Co. over its easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property.

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire US-based SpringWorks Therapeutics for $3.9 billion, a move aimed at strengthening its oncology ...

The company didn't provide an outlook for 2025. - Merck (MRK) shares rise after the company agreed to buy SpringWorks Therapeutics Inc. for $47 per share in cash, representing an equity value of ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03.

(RTTNews) - Merck KGaA, and SpringWorks Therapeutics, Inc. (SWTX) announced they have entered into a definitive agreement for Merck KGaA to acquire SpringWorks. The purchase price of $47 per share ...